imfinzi.com 的前十大競爭對手

tagrissohcp.com

Learn about TAGRISSO® (osimertinib) for the treatment of metastatic and resectable EGFRm NSCLC by contacting a representative.

rybrevanthcp.com

The official healthcare provider website for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and RYBREVANT® (amivantamab-vmjw), treatments for EGFR+ mNSCLC. See full Prescribing & Safety Information.

rybrevant.com

View helpful FAQs and term definitions about RYBREVANT FASPRO™ and RYBREVANT®, treatment, and support programs. See full Prescribing & Safety Information.

tagrisso.com

learn about tagrisso® (osimertinib), a targeted treatment option for people with certain types of egfr+ non-small cell lung cancer (nsclc). talk to your doctor to see if tagrisso is right for you.

keytrudahcp.com

health care professionals may find information about fda-approved indications for keytruda® (pembrolizumab) along with keynote clinical trials and treatment guidelines.

braftovi.com

Learn about BRAFTOVI® (encorafenib) an Rx combination treatment for certain BRAF positive (BRAF+) cancer types and see risks & benefits.

cabometyxhcp.com

CABOMETYX® (cabozantinib) is a multi-indication cancer treatment FDA-approved for 1L & 2L aRCC, 2L HCC and 2L DTC. See Important Safety Information.

vyloy.com

Find answers to frequently asked questions about VYLOY® and advanced stomach cancer. Please see full Prescribing Information.

padcev.com

Learn more about PADCEV®. Find information on efficacy, dosing, resources, and more. Please see full Patient Information, including Serious Side Effects.

orserdu.com

Evaluate ORSERDU®, a treatment option for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer following disease progression on endocrine therapy.